CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance patient safety by improving the reporting and management of adverse drug reactions. It seeks to build a network of stakeholders to share knowledge and implement evidence-based practices to reduce medication-related harm.
Medicines are one of the most common health interventions.
Expenditure on pharmaceuticals range from 10–20 % of all health expenditure in rich countries & from 20–60 % in poor countries.
Knowledge of appropriate & safe medicines has grown.
But the incidence of medicines adverse effects remains high.
In a UK study 6.5% of hospitals admissions were related to an adverse drug reaction (ADR).
And as many as 10% of hospital admissions may result in death or disease due to errors, half of which may be…
Stiftelsen WHO Collaborating Centre for International Drug Monitoring
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Uppsala
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
NEDERLANDS BIJWERKINGEN CENTRUM LAREB
Netherlands, S Hertogenbosch
Type: Research institute
Activity type: Research Organisations
SME: No
United Kingdom, London
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
